Prevention and treatment of bone metastases
RE Coleman - Nature reviews Clinical oncology, 2012 - nature.com
Nature reviews Clinical oncology, 2012•nature.com
Bone-targeting treatments have transformed the quality of life of patients with metastatic
bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—
as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-
targeting treatments to prevent metastasis from breast and prostate cancers.
bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—
as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-
targeting treatments to prevent metastasis from breast and prostate cancers.
Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.
nature.com
